Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats by Kaminski, Henry J. et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Neurology Faculty Publications Neurology
2016
Differential RNA Expression Profile of Skeletal
Muscle Induced by Experimental Autoimmune







See next page for additional authors
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_neuro_facpubs
Part of the Nervous System Diseases Commons, and the Neurology Commons
This Journal Article is brought to you for free and open access by the Neurology at Health Sciences Research Commons. It has been accepted for
inclusion in Neurology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
APA Citation
Kaminski, H. J., Himuro, K., Alshaikh, J., Gong, B., Cheng, G., & Kusner, L. L. (2016). Differential RNA Expression Profile of Skeletal
Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats. Frontiers in Physiology, (). http://dx.doi.org/10.3389/
fphys.2016.00524
Authors
Henry J. Kaminski, Keiichi Himuro, Jumana Alshaikh, Bendi Gong, Georgiama Cheng, and Linda L. Kusner
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/smhs_neuro_facpubs/349
  
 
Differential RNA Expression Profile of Skeletal Muscle
Induced by Experimental Autoimmune Myasthenia
Gravis in Rats
 
Henry Kaminski1*, Keiichi Himuro2, Jumana Alshaikh1, Bendi Gong3, Georgiama Cheng4,
Linda Kusner5
 
1Neurology, George Washington University, USA, 2Neurology, Chiba University, Graduate
School of Medicine, Japan, 3Pediatrics, Washington University, USA, 4Pathobiology,
Cleveland Clinic, USA, 5Pharmacology & Physiology, George Washington University, USA
 Submitted to Journal:
 Frontiers in Physiology
 Specialty Section:




 Original Research Article
 Received on:
 14 Sep 2016
 Accepted on:
 24 Oct 2016
 Provisional PDF published on:
 24 Oct 2016




Kaminski H, Himuro K, Alshaikh J, Gong B, Cheng G and Kusner L(2016) Differential RNA Expression




© 2016 Kaminski, Himuro, Alshaikh, Gong, Cheng and Kusner. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and
reproduction in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted academic





This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF
and full text (HTML) versions will be made available soon.
 




  Kaminski, 1 
 
Differential RNA Expression Profile of Skeletal Muscle 
Induced by Experimental Autoimmune  
Myasthenia Gravis in Rats 
 
Henry J. Kaminski,1 Keiichi Himuro,2 Jumana Alshaikh,1 Bendi Gong,3 Georgiana 
Cheng,4 Linda L. Kusner5 
 
Departments of Neurology1, Pharmacology & Physiology5 
George Washington University, Washington, DC1 
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan2 
Department of Pediatrics, Washington University, St. Louis, MO3 
Department of Pathobiology, Cleveland Clinic, Cleveland, OH4 
 
Key words: Myasthenia gravis, acetylcholine receptor, autoimmunity, gene expression 
profiles, skeletal muscle, metabolism. 
 
Running Title: RNA Profile of Experimental Myasthenia 
 
Address Correspondence to Henry J. Kaminski, MD, George Washington University, 






  Kaminski, 2 
 
Abstract 
The differential susceptibility of skeletal muscle by myasthenia gravis (MG) is 
not well understood.  We utilized RNA expression profiling of extraocular muscle 
(EOM), diaphragm (DIA), and extensor digitorum (EDL) of rats with experimental 
autoimmune MG (EAMG) to evaluate the hypothesis that muscles respond differentially 
to injury produced by EAMG.  EAMG was induced in female Lewis rats by 
immunization with acetylcholine receptor purified from the electric organ of the Torpedo.  
Six weeks later after rats had developed weakness and serum antibodies directed against 
the AChR, animals underwent euthanasia and RNA profiling performed on DIA, EDL, 
and EOM.  Profiling results were validated by qPCR.  Across the three muscles between 
the experiment and control groups, three hundred and fifty-nine probes (1.16%) with 
greater than 2 fold changes in expression in 7 of 9 series pairwise comparisons from 
31,090 probes were identified with approximately two-thirds being increased. The three 
muscles shared 16 genes with increased expression and 6 reduced expression.  Functional 
annotation demonstrated that these common expression changes fell predominantly into 
categories of metabolism, stress response, and signaling.  Evaluation of specific gene 
function indicated that EAMG led to a change to oxidative metabolism. Genes related to 
muscle regeneration and suppression of immune response were activated.  Evidence of a 
differential immune response among muscles was not evident.  Each muscle had a 
distinct RNA profile but with commonality in gene categories expressed that are focused 
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Introduction 
Myasthenia gravis (MG) is caused by antibodies, primarily directed at skeletal 
muscle nicotinic acetylcholine receptor (AChR), which lead to a reduction of AChR 
number and damage of the muscle endplate, producing a failure of neuromuscular 
transmission that results in weakness.[1]  The pathophysiology would be expected to 
compromise muscles to a similar extent, but clinical investigation for over a hundred 
years have demonstrated a preferential involvement of certain muscles.  Explanations for 
the differential targeting may lie in subtle aspects of the antibody-antigen engagement in 
vivo but are more likely to entail variations in the properties of the targeted muscles. 
The differential involvement of skeletal muscles by neuromuscular disorders, 
including MG, is poorly understood but likely is a function of disease specific 
pathophysiology and properties of the individual muscles.  In particular, differences in 
functional requirements of a muscle impact the gene expression pattern. In its role in eye 
movement extraocular muscle (EOM) is constantly, and this is reflected in its 
transcriptional profile differing from jaw and leg muscle in expression of glycogenic and 
gluconeogenic genes.[2; 3] Further, lactate is a significant substrate for EOM, which is in 
stark contrast to other skeletal muscles that excess lactate produces fatigue.[4]  Similarly, 
as reflected in fiber-type distribution diaphragm also possess properties that support its 
high energy requirements compared to leg muscles.[5]  The consequences of 
neuromuscular disorders on whole body metabolism may then also be expected to 
differentially impact muscles. 
Extraocular muscle (EOM) are preferentially involved by MG and several non-
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vision with even minimal weakness of an EOM, but a similar level of weakness of 
another muscle would not produce clinically evident symptoms.  The extremely rapid 
firing rate of ocular motor neurons and the immature appearance of their neuromuscular 
junctions may place the EOM at particular risk for a neuromuscular transmission 
disorder. The RNA expression profiles of EOM, extensor digitorum longus (EDL), and 
diaphragm (DIA) muscle from rats with passively-transferred MG (PTMG) [6] produced 
by administration of acetylcholine receptor antibody supports a greater degree of injury to 
EOM,[7] which supports that EOM has unique immunological characteristics that places 
them at specific risk for MG.[8; 9; 10] 
EAMG induced in rodents by immunization with purified AChR mimics the 
human disease much better than administration of AChR antibodies.[11]  Within 6 weeks 
of a single immunization, rats generate AChR antibodies and then weakness, which 
improves with cholinesterase inhibition.  As with humans, infiltrates of inflammatory 
cells are not prominently observed in muscle,[12; 13] which is in contrast to PTMG.  In 
order to assess, variations in intrinsic response of muscles to EAMG, we used RNA 
expression profiling of diaphragm (DIA), extensor digitorum longus (EDL), and EOM to 
assess their response.   
 
Materials and Methods 
Ethics Statement for Animal Use 
Six to eight week old female Lewis rats weighing 120 -150 g (Harlan, 
Indianapolis, IN) were maintained in the Case Western Reserve University School of 
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standards concerning appropriate housing, cage cleaning procedure, air purity, feed, 
temperature, humidity, light and dark cycle. Animals were housed in isolator cages in a 
pathogen-free environment, and rodent chow and water were provided ad libitum. A 
veterinarian is on staff and will be observing the health of the animals throughout the 
study. All animal studies were conducted according to protocol approved by the Case 
Western Reserve Institutional Animal Care and Use Committee Approval Number 
030185.  All efforts were made to minimize animal suffering.  Tissue was harvested after 
euthanasia by CO2 asphyxiation. 
Induction and Evaluation of EAMG 
Torpedo AChR was purified from the electric organ of Torpedo californica by 
affinity chromatography as previously described.[14]  Rats were immunized once at the 
base of the tail by subcutaneous injection of purified Torpedo AChR (40 µg/rat in 200 µl) 
emulsified in complete Freund’s adjuvant supplemented with additional nonviable 
Mycobacterium tuberculosis H37RA (0.5 mg/rat; Difco Laboratories, Detroit, MI). 
Control rats were immunized with the same volume of adjuvant without AChR.  Rats 
were monitored for evidence of weakness and their status scored based on a commonly 
used motor strength scale, as follows: 0 = can grip and lift lid of a cage, 1 = can grip but 
cannot lift the lid of a cage, 2 = unable to grip cage lid, 3 = unable to grip and has hind 
limb paralysis, 4 = moribund.  Weight was assessed initially on a bi-weekly basis and 
then every other day when weakness or weight loss became evident.   
Tissue Preparation 
After euthanasia, EOM rectus muscles, DIA, and EDL muscles were dissected 
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for each of three independent replicate groups. The study was then repeated twice to 
produce the 3 replicates for the array analysis.  This procedure served to limit inter-
animal and inter-experiment variability. Tissues were snap frozen in liquid nitrogen and 
stored at -80°C until use.  
Serum AChR Antibody Determination 
Blood was obtained at week 2 by tail vein puncture and after euthanasia from the 
heart at week 6.  Serum was isolated and AChR antibody determination made by ELISA.  
Ninety-six-well immune-plates (Corning; New York, NY) were saturated with 200 μl (10 
μg/ml AChR) in PBS buffer (0.1% Tween20 in PBS) per well and incubated overnight at 
4oC.  After washing twice with PBST buffer, the plates were incubated with 200 μl of 
blocking buffer (5% of bovine serum albumin in PBS) per well at 37oC for 0.5-1.5h. The 
plates were washed twice with PBST buffer and then incubated for 1 h at 37oC with 100 
μl of the diluted test serum (1:200). The plates were then washed twice with PBST, each 
well received 100 μl of peroxidase-labeled rabbit anti-rat IgG and incubated for 1 h at 
37oC. One hundred μl of substrate solution (0.05 M citrate, 0.1 M NaCl/Pi, 2,20-Azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid), 0.03% H2O2} was incubated for 15 min at 
37oC. Color development was measured at 405 nm using a microplate reader. 
Immunohistochemistry   
For analysis of C9 deposition at neuromuscular junctions, cryosections of muscles 
were prepared. Sections were incubated with rabbit anti-ratC9 (gift of M. E. Medof) and 
then double-stained with FITC-labeled goat anti-rabbit Ab and Texas red–labeled αBTX 
(2 μg/ml; Molecular Probes Inc., Eugene, Oregon, USA) to identify neuromuscular 
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(Nikon Instruments Inc., Melville, New York, USA) and analyzed using ImagePro 
software (Media Cybernetics, Silver Spring, Maryland, USA).  
Sample Preparation for Microarrays 
The muscle harvested from DIA, EDL and EOM of four rats pooled from four 
EAMG or control rats during RNA isolation forming three samples for subsequent array 
analysis.  Total RNA was extracted using TRIzol reagent (GibcoBRL, Rockville, MD).  
RNA pellets were cleaned by RNasey kits and re-suspended at 1 mg RNA/ml DEPC-
treated water and 5 μg was used in a reverse transcription reaction (SuperScript II; Life 
Technologies, Rockville, MD) to generate first strand cDNA.  Double strand cDNA was 
synthesized and used in an in vitro transcription (IVT) reaction to generate biotinylated 
cRNA.  Fragmented cRNA (15 μg) was used in a 300 μl hybridization cocktail containing 
herring sperm DNA and BSA as carrier molecules, spiked IVT controls, and buffering 
agents.  A 200 μl aliquot of this cocktail was used for hybridization to Affymetrix rat 
REA230 (Santa Clara, CA) microarrays for 16 hrs at 45oC.  The manufacturer’s standard 
post-hybridization wash, double-stain, and scanning protocols used an Affymetrix 
GeneChip Fluidics Station 400 and a Hewlett Packard Gene Array scanner. 
Microarray data analysis   
Raw data from microarray scans were analyzed with Affymetrix GCOS 2.0.  
GCOS evaluates sets of perfect match (PM) and mismatch (MM) probe sequences to 
obtain both hybridization signal values and present/absent calls for each transcript. 
Microarrays were scaled to the same target intensity and pairwise comparisons were 
made between experimental and control samples. Transcripts defined as differentially 
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replicate comparisons, based upon Wilcoxon’s signed rank test (algorithm assesses probe 
pair saturation, calculates a p value and determines increase, decrease, or no change 
calls).  Any transcripts with expression intensity below 400 (5 time of background level) across 
all the samples were also excluded since distortion of fold difference values results when 
expression levels are low and may be within the level of background noise.  Data were 
visualized as a hierarchical cluster analysis generated (Genespring software, version 7.2; 
Silicon Genetics, Redwood city, CA). Annotation was done according to Affymetrix 
NetAffyx Gene Ontology database.  Data for the 18 microarray experiments used in this 
report can be found in the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO), series accession number GSE11465. 
Quantitative real-time PCR (qPCR) 
Select transcripts were reanalyzed by qPCR, using the same samples as in the 
microarray studies.  Transcript-specific primers (Supplemental Table 1) were designed 
using Primer Express 2.0 software (Applied Biosystems, Inc. (ABI), Foster City, CA) and 
specificity confirmed by NCBI BLAST.  Reverse transcription was carried out on 1 µg 
total RNA with Invitro Reverse transcription reagent.  qRT-PCR used SYBR green PCR 
core reagent in 24 µl volume, with an ABI PRISM 7000 Sequence Detection System.  
GAPDH was used as an internal positive loading control.  Fold change values represent 
averages from triplicate measurements, using the 2-ΔΔCT method.[15] 
 
Results 
Confirmation of EAMG Induction 
After the immunization, serum AChR antibody levels of the experimental group 
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undetectable in the control group throughout the experiment, while all rats in the 
experimental group developed elevations of AChR antibody levels.  At weeks 4 to 5, 
weight loss was observed in EAMG rats and weakness became evident as assessed by 
reductions of grip strength and reduction of observed movement (data not shown).  At 
week 6 experimental rats had a mean weight loss of 11.5% ± 3.45 compared to their peak 
weight, while control rats had a mean weight gain of 5.9% ±1.0 compared to the previous 
week weight.  All rats reached the end of the experiment with no need for early 
euthanasia.   To assess for activation of the complement system, we evaluated C9 
deposition from control and experimental rats.  Endplates from all control muscles had α-
BTX staining and no C9 staining.  Endplates from all EAMG muscles demonstrated 
endplates C9 deposition which overlapped with α-BTX fluorescence (not shown). 
RNA Profile Analysis 
To identify global alterations in gene expression related to EAMG in EOM, DIA, and 
EDL, RNA was prepared and processed for microarray hybridization from AChR 
immunized and control CFA immunized rats.  The percentage of transcripts detected as 
present in each sample ranged from 48 to 63.7 with average 53.3 ± 4.2. The GAPDH 
probes 3 to 5 ratio ranged from 1.06 to 2.66 with average 1.27 ± 0.35, indicating RNA 
quality was appropriate and the hybridization was successful among the samples.  The 
results are consistent with our previous expression profiling studies.[7]    
We found a total of 359 transcripts (Figure 1) altered by two fold in 7 of 9 series 
pairwise comparisons between the experimental and control groups among the muscles.  
Figure 1 shows the degree of overlap in gene differences across the three muscles.  DIA 
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205 genes changed, 100 were up-regulated and 105 down-regulated, and EOM have 116 
changed, 85 are up-regulated and 31 down-regulated. Using the 359 transcripts, 
hierarchical cluster analysis (Figure 2) demonstrated a distinct expression pattern of the 
genes found to be differentially influenced by EAMG across the three muscles.  
Comparison of the differentially expressed transcripts identified 16 upregulated and 6 
downregulated transcripts shared among the three muscles (Table 1).   Functional 
annotation of the differentially expressed genes identified more than a half are involved 
in signal transduction, metabolism and transcription regulation, suggesting the muscles 
experience adaptation to EAMG directly and to metabolic alterations associated with the 
disease (Table 2, Supplemental Table 2).  Alteration of expression of ten genes (Enc1, 
Nfkbia, Nfix, Errfi1, Glipr2, Dyrk2, Hbb, Hba-a1, Pnpla2, Galnt12) were identified 
common to the three muscles as a response to EAMG.  The roles of these genes fell into 
two broad categories: muscle repair and suppression of inflammatory signals.  The 
Discussion provides detailed consideration of expression alterations. 
In our previous study of passive transfer MG and a study of mdx mice,[7; 16] we 
determined a disease load index (DLI), which sums the absolute fold change values of 
increased and decreased transcript to provide a single transcriptional index of EAMG 
pathology.  In the present investigation, EDL had the greatest DLI (Figure 3), although 
EOM had the greatest total of increased transcript levels with 351 total fold increase to 
101 total fold decrease.  The greater DLI of EDL suggests a greater transcriptional 
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Validation of RNA Profile  
We used qPCR to validate results of the RNA profiling.  We determined 
expression levels of 14 transcripts to provide a broad assessment of the array results. 
Three upregulated transcripts (Ankrd1, Mt1a, Cebpd1) and one down regulated transcript 
(Neu2) that by RNA profiling had been identified as altered across all three muscles.  We 
assessed transcripts that were previously identified as altered by EAMG (Chrna1, Pde4b, 
Cts1, Trm63)[7; 17] or involved in inflammation (NFkB, Ctse).  We evaluated transcripts 
that were increased in the RNA profiling of EOM alone (Plunc, Pax6, Rgs2)[18] or 
known to be increased in EOM (Csrp3).[19]  RNA profiling and qPCR results correlated 
well with correlation coefficient of 0.9. (Table 3). 
 
Discussion 
We found distinct genomic signatures for DIA, EDL, and EOM in response to 
EAMG with a small number of gene alterations shared among the muscles (Figure 1).   
The results of array analysis were validated by qPCR with a significant correlation.  
Across the muscles, there was wide variation in the specific gene changes, but a 
commonality of genes that were altered occurred in cell signaling, transcriptional factors, 
and metabolism categories.  Genes associated with muscle injury repair were 
upregulated.  Only, a few genes primarily associated with the immune system or 
inflammation were modified by EAMG, however these were focused on genes that would 
suppress inflammation.  The observation is consistent with histology of muscle of human 
MG, and EAMG in the chronic stage, which does not have evidence of inflammation.[11; 
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EAMG, by extension human MG, lacks inflammatory infiltrates in muscle after the acute 
induction stage. 
A critical issue that cannot be addressed by our investigation is the degree to 
which individual mechanisms alter transcriptional profiles.  For example, reduced muscle 
activity produced by EAMG, or for that matter, passive transfer MG in our previous 
investigation influences the gene expression pattern. The EOM in particular have unique 
neuromuscular transmission properties with synapses subject to extremely high 
stimulation rates by their motor neurons and a reduction in muscle stimulus would likely 
lead to transcriptional alterations.[21]  Knowing that post-synaptic damage is likely to 
influence presynaptic properties, we cannot dissociate our results to one specific 
alteration produced by EAMG.[22]  As we discuss the influence of alterations in whole 
body metabolism produced by weight loss further will alter gene expression of each 
muscle in a differential pattern given their unique characteristics. 
 
Gene expression alterations unique to EAMG and common to all muscles  
The enhanced expression of five genes (Nfix, Enc, Errfi1, Glipr2, Dyrk2, 
Galnt12) modified by EAMG appear to enhance muscle repair.  Nfix, is a transcription 
factor known to be involved in myogenesis and muscle regeneration.[23]  Enc1 is an 
actin-binding protein, which is involved in neuronal process formation.[24; 25] Its 
expression has not been observed previously in muscle, and presumably, Enc1 would 
function to aid recovery of damaged neuromuscular junctions.  Errfi1 (also known as 
Mig6) is an inhibitor of epidermal growth factor signaling and is increased with cell stress 
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a response to muscle injury, either from increased oxidative metabolism or 
neuromuscular junction injury.[26]  Our previous PTMG profiling study identified a 
homolog of Mig6 to be upregulated across all three muscles. Glipr2 is a signaling 
molecule, which has not been well-characterized, but is upregulated in sciatic nerve 
injury from experimental  diabetes.[27]  Glipr2 is involved in transition of epithelial to 
mesenchymal cells by way of epidermal growth factor signaling pathways,[28] which are 
also known to be involved in recovery from muscle injury.  Dyrk2 encodes a tyrosine 
kinase, which negatively regulates growth of cardiac myocytes,[29] and the reduced 
expression of Dyrk2 in EAMG would be expected to promote recovery from injury.  
Galnt12 encodes an acetylgalactosaminyl transferase and polymorphisms in the gene are 
associated colonic cancer.[30; 31]  The increased expression of Galnt12 likely enhances 
protein modifications that may be involved in the regenerative process.   
Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha) is a transcriptional factor with increased expression among all three 
muscles exclusive to EAMG.  Nfkbia inhibits cell apoptosis by inhibition of caspase.  In 
rats, Nfkbia is decreased in diet-induced obesity and hyperlipidemia.  Nfkbia can inhibit 
NFκB by direct binding and regulation of transcriptional responses to NFκB, including 
cell adhesion, immune and proinflammatory responses, apoptosis, differentiation and 
growth.[32]  In addition to its effects on contractility, Fkbp5 modulates NFκB activity 
and in tandem with Nfkbia would reduce inflammatory signaling in muscle.[33]  
In addition, to the primary categories of muscle repair and immunosuppression, 
there were three gene changes that would influence metabolism. The Dyrk2 gene product 
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be a response to a shift to fatty acid oxidation (see discussion below). Pnpla2 encodes a 
lipase that hydrolyzes fatty acids from triacylglycerol and mutations of the gene produce 
a myopathy.  The upregulation of the gene’s expression is also in keeping with the overall 
shift to fatty acid oxidation.[35] This change to oxidation is a reflection of decreased 
availability of glucose and would further be reflected in a reduction of muscle force 
generation.  The reason for the reduced expression of the two hemoglobin gene 
transcripts (Hbb, Hba-a1) in muscle is not clear.   
Gene Expression Changes Specific to EAMG 
 Consistent with overall profile, alterations of genes involved in metabolism were 
the most common category for EOM. The gene encoding the alpha subunit of the 
acetylcholine receptor was increased in response to EAMG in skeletal muscle an EOM 
previously.[36; 37] We evaluated expression of four genes by qPCR expressed at high 
levels in EOM, three of which appear to be responsive to injury.  Pax6 is a transcriptional 
regulator involved in eye development and during development influences muscle 
formation.[38]  Its increased expression in EOM suggests that it may be responding to 
injury, perhaps through the elevated activity of muscle satellite cells in EOM.[39]  Rgs2, 
a regulator of G-protein signaling, also appears to be involved quiescent stem cell 
renewal of muscle.[40] Cspr1, a member of the LIM protein family, has many functions 
in skeletal and cardiac muscle including myocyte differentiation.[41]  Plunc is expressed 
in nasal epithelial tissue and has a bactericidal effects suggesting a role in innate 
immunity.[42]  Its upregulation in EOM in response to EAMG suggests a response to 
antibody-mediated injury but otherwise is unclear. 
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PTMG is produced by administration of either mono- or poly-clonal antibody 
specifically directed towards the autoantigen, in the present study the skeletal muscle 
AChR.[6]  The model mimics the final effector pathway of autoantibody destruction 
observed in humans with MG.  The onset of muscle injury is rapid and is accompanied by 
muscle inflammation not seen in the active model or the human disease.  In our previous 
study of PTMG of EDL, DIA, and EOM,[7] RNA profiling demonstrated a greater 
number of gene alterations, a preponderance of immune-related gene expression 
alterations, and EOM had the greatest DLI.  There were specific gene alterations common 
among the three muscles and interestingly among these, several were shared with our 
present RNA profile of EAMG.[7]  These ten genes were Ankrd1, Gpnmb, Cebpd, Pdk4, 
Angptl4, Ddit4, Gadd45a, Mt1a, Fmo2, and Fkbp5. 
Evidence of immunosuppressive response across muscles. Ankrd1 has been found to 
be increased in response in several forms of muscle injury, including denervation, motor 
neuron disease, stretch, and starvation.[43; 44; 45]  Ankrd1 also down regulates NFκB as 
an anti-inflammatory signal,[46] which would contribute to the lack of local muscle 
inflammation in EAMG, while its increase in PTMG may be a response to acute 
inflammation observed.  Osteoactivin (Gpnmb) is a type I transmembrane glycoprotein 
that is expressed in numerous tissues including skeletal muscle.  Osteoactivin has 
immunosuppressive effects[47] and promotes maintenance of innervation,[48] these 
properties would aid recovery from injury by EAMG.  In contrast to the PTMG study in 
which an inflammatory infiltrate was present, we can be confident that the source of 
Gpnmb transcripts is from the skeletal muscle.  The increase of Cebpd, a transcriptional 
factor known to reduce pro-inflammatory cytokines,[49; 50] would also serve  to limit 
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muscle inflammation in response to EAMG.[51]  Increased expression of cortisone-
regulated target genes also would indicate a general anti-inflammatory state, which would 
also be reflected in metabolic alterations. 
Metabolic Alterations Influenced by EAMG 
The other genes in common across MG models and the three muscles under study 
were primarily involved in metabolism.  At the time of euthanasia, rats were 
demonstrating weight loss, however, in comparison an RNA profile of rat gastrocnemius 
after fasting, the gene alterations observed with EAMG are distinct.[52]  The pyruvate 
dehydrogenase kinase gene is a key regulatory enzyme in skeletal muscle involved in 
switching the primary energy source from glucose to fatty acids in response to 
physiological conditions. Transcription of the PDK4 gene is activated by fasting in a 
tissue-specific manner[53; 54] and after both short-term high-intensity and prolonged 
low-intensity exercise.  Angptl4 (an inhibitor of lipoprotein lipase) expression was 
increased, and its protein product is directly involved in reduction of glucose utilization, 
enhanced lipid metabolism, and increased insulin sensitivity during fasting.[55; 56]  
Metallothioneins are low molecular weight, cysteine–rich zinc binding proteins and serve 
to protect cells after oxidative stress injury.[57]  Mt1a is a metallothionein, which is 
induced in skeletal muscle of animals in catabolic states and physiological stress 
situations, [58] which also result in elevated levels of glucocorticoids and reactive 
oxygen species.  Another metallothionein, Mt1e, was elevated among all muscles in the 
present study, but not the PTMG investigation.  The increase in flavin-containing mono-
oxygenase 2 (Fmo2) also would serve as a response to an increase in reactive oxygen 
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directly or indirectly may increase intracellular reactive oxygen species with muscle 
responding with a potential adaptive response to systemic metabolic alterations.  The 
uniform response to stress is further confirmed by increased expression of Ddit4 and 
Gadd45a.  Ddit4 is a DNA-damage-inducible transcript, inhibits mTOR (downstream 
kinase of IGF pathway) functional control of cell growth in response to energy stress.[60; 
61]  Gadd45a is activated by physiological stress and DNA damage serving to modulate 
cell cycle arrest and apoptosis.[62]  Increased Cebpd expression occurs with denervation 
and food deprivation.[63; 64]  In skeletal muscle Cebpd expression would moderate 
myostatin expression and potentially produce muscle atrophy.[65]   
Muscle contractility gene influences  
The increase of Fkbp5 (FK506 binding protein) may serve to moderate calcium 
activation through the ryanodine receptor.[59]  In PTMG, muscle contractility is 
compromised to a greater extent than expected from the neuromuscular transmission 
defect alone.  An increase in Fkbp5 would reduce influx of calcium and negatively 
impact muscle contractility.  Muscle force generation is also reduced in isolated muscle 
preparations treated with sera from patients with MG.[66; 67] In EDL, Zfn28 was found 
to be increased.  Zfn28 is a RING zinc finger protein family member, which localizes to 
the Z-line and M-line lattices of myofibrils. In vitro binding studies indicate that Zfn28 
binds to titin near the region responsible for kinase activity. Since these family members 
can form heterodimers, this suggests that these proteins may serve as a link between titin 
kinase and microtubule-dependent signal pathways in muscle.[68]   Alterations in the 
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Neu2 was the only gene reduced in expression among all three muscles and 
common to the RNA profile of PTMG.  Neu2 encodes a glycohydrolytic enzyme that is 
primarily expressed in mature muscle.[69]  The function of Neu2 has not been well 
characterized but is considered to enhance muscle regeneration and development, and its 
reduced expression in EAMG may compromise muscle repair.  
RNA profile across muscles 
Numerous clinical observations demonstrate a differential effect of neuromuscular 
disorders on specific muscle groups.  Our previous RNA expression analysis of PTMG 
showed that EOM had the greatest DLI, which we had considered consistent with the 
greater susceptibility of EOM to disease observed in human MG.  In the PTMG, 
transcript alterations were largely related to immune activity.  In EAMG, EDL had the 
greatest transcriptional response to EAMG but this was related to preponderance of 
metabolic alterations.  EOM given their specialized function in moving the globe and 
small size would not contribute to whole body metabolic control in contrast to EDL and 
other large muscles, which are critical to regulation of glucose, fatty acid, and amino acid 
synthesis and utilization.   
Regarding specific gene expression alterations of note, the AChR subunit α-
subunit was increased consistent with previous EAMG investigations.   The expression 
difference was likely detectable in EOM because of its high innervation ratio and the 
increased expression reserved to subsynaptic nuclei.[70]  Spp1 (osteopontin) was 
upregulated in EOM. OPN is a glycosylated phosphoprotein originally identified in bone 
matrix, but now found to be produced in many cell types. OPN is considered a pro-
inflammatory cytokine, and increased levels have been associated with inflammatory 
Provi
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muscle disease[71; 72] [73] and muscular dystrophy.[74]  Its elevated expression is in 
distinction from the upregulation of an anti-inflammatory state of RNA profile, which 
would support the contention that EOM has a unique immune environment, which in 
certain conditions enhances susceptibility to autoimmune and inflammatory disorders.[9] 
Metallothionein family members are highly induced by catabolic states where 
found to be elevated across all muscle groups.[75]  Foxo1a, a transcription factor, was 
increased in EDL and diaphragm by EAMG and is also increased in states of catabolism. 
[75] Cathepsin L was elevated in EDL with EAMG which is also the case for muscle 
atrophy. 
Clinical Relevance 
As with any animal study there are limits in application of results to human 
disease.  The rat and human immune systems possess unique characteristics, and the 
exogenous administration of autoantigen with adjuvant does not mimic the spontaneous 
development of the breakdown in tolerance of the human disease.[11]  However, the 
ultimate common pathway of antibody attack with complement activation is shared 
between EAMG and human MG.  The subsequent influence of generalized weakness on 
the animal and human also are likely to have commonalities.  
The EAMG rats developed moderate weight loss, which is likely driving the gene 
expression changes related to metabolism.  The three muscles shared similar responses in 
shifting to from glycolytic to oxidative metabolism.  In keeping with this alteration 
pathway the same response in terms of stress and free radical metabolism pathways, and 
a number of nuclear receptors target genes involved in lipid and glucose metabolism were 




  Kaminski, 20 
 
moderated pathways were inhibited.  This was true for EOM, which relies on glucose and 
lactate for generation of energy.[2; 4]  These observations demonstrate that RNA profiles 
related to metabolism undergo significant alterations by EAMG.  
In muscle, there are four pathways for protein degradation: lysosomal proteases 
including the cathepsins; calcium-dependent proteases; cytosolic ATP-dependent 
(proteasome); and cytosolic ATP-independent proteolytic pathways.  In EDL and DIA 
FBXO32(atrogin-1) and Trim63(MuRF-1) were upregulated, these two genes are E3 
ubiquitin-ligase, which are involved in ubiquitin-proteasome proteolysis pathway and are 
markers of muscle atrophy.[76; 77]  Their common transcription factor, Foxo1a was also 
increased in expression.[36; 78]  Proteasome pathway related genes were more 
prominently expressed in EDL compared with DIA and EOM.  EDL can be considered a 
“standard” skeletal muscle, which participates in regulation of whole body metabolism.  
These data suggest the EAMG leads to accelerated proteolysis, which is also likely to 
occur among patients with significant weakness.  Since the active model of EAMG more 
closely mimics MG in humans, it is likely that metabolic alterations should be a focus of 
investigation in clinical studies. 
Conclusion    
 Our study demonstrates the complex alterations occurring on a transcriptional 
level in response to the direct effects of acetylcholine receptor antibody attack on the 
neuromuscular junction as well as secondary influences on nerve-muscle communication 
and development of weight loss. In our investigation we cannot uncouple these effects.  
We show that alterations in metabolism related genes occurs, an anti-inflammatory 
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EOM would have a greater DLI, this was not the case indicating that the reasons for the 
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Table 1. Gene Transcript Changes Common to All Muscles 
Symbol Name  DIA EDL EOM Classification
Ankrd1 ankyrin repeat domain 1 5.6 5.5 3.6 transcription
Cebpd  CEBP delta 2.9 8.4 2.5 transcription
nfix nuclear factor I/X -4.7 -2.0 -2.9 transcription
Nfkbia nuclear factor of kappa light chain 2.3 2.8 2.3 transcription
Ddit4 DNA-damage-inducible transcript 4 3.1 4.7 3.1 stress
Gadd45a growth arrest and DNA-damage-inducible 45 alpha 2.3 2.1 2.5 stress
Mt1a metallothionein 1a 4.7 8.2 3.3 stress
Errfi1 ERBB receptor feedback inhibitor 1 2.9 3.0 2.8 stress
Mt1e metallothionein 1e 3.0 5.5 2.8 stress
Gpnmb glycoprotein (transmembrane) nmb 2.2 3.1 5.2 signal
Glipr2 Golgi- associated PR-1 protein -2.4 -2.4 -2.2 signal
Dyrk2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 -2.4 -2.3 -2.4 signal
Enc1 ectodermal-neural cortex 1 2.4 2.1 2.1 signal
Hbb hemoglobin beta chain complex -4.8 -2.4 -3.9 metabolism
Neu2 neuraminidase 2 -2.9 -4.0 -2.2 metabolism
Hba-a1 hemoglobin alpha 2 chain -3.6 -2.3 -3.5 metabolism
Pnpla2 patatin-like phospholipase domain containing 2 2.4 2.8 2.1 metabolism
pdk4  pyruvate dehydrogenase 2.4 3.5 2.3 metabolism
fmo2  flavin containing monooxygenase 2 4.0 3.0 3.9 metabolism
galnt12 GalNAc transferase 12 3.5 2.8 2.6 metabolism
Angptl4 angiopoietin-like 4 6.4 6.2 17.5 metabolism
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Table 2.  Transcript Changes in Percent by Category 
 Shared EOM  DIA EDL 
Transcription 18 5 7 19 
Stress 22 0 1 5 
Metabolism 32 21 6 17 
Signaling 18 33 44 25 
Proteolysis 0 5 4 5 
Muscle-Related 0 4 1 5 
Inflammatory 5 8 7 2 
*ECM 5 3 0 2 
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Table 3. Fold Change Comparison Between Real-Time PCR and Microarray 
 
 DIA  EDL  EOM  
GENE SYMBOL qPCR Array qPCR Array qPCR ARRAY 
ANKRD1 11.7 6.2 8.1 5.5 5.6 3.2 
MT1A 4.2 4.7 4.8 8.2 5.3 3.4 
CEBPD1 5.3 3.0 6.5 4.5 3.3 2.2 
PDE4B 3.2 2.0 2.8 1.7 2.0 1.3 
CTS L 2.8 1.8 2.7 2.8 2.2 1.4 
CHRNA1 2.1 1.9 2.5 1.7 3.7 2.3 
CTS E  1.9 1.2 0.9 1.0 7.5 7.6 
CSRP3 5.9 2.4 5.4 3.3 3.0 1.4 
NEU2 -3.2 -2.7 -3.8 -4.0 -1.9 -2.2 
NFKB 1.1 1.0 1.8 1.3 1.3 1.0 
PAX6 N/A 0.5 N/A 1.3 6.7 4.0 
PLUNC N/A 0.9 N/A 1.0 4.1 3.0 
RGS2 1.4 1.1 1.0 0.8 -1.8 -1.3 
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Figure 1. Venn diagrams showing the numbers of differentially expressed transcripts in 
EAMG muscles compared with control rats shared by or unique to DIA, EDL and EOM. 
 
Figure 2. Hierarchical cluster analysis using 359 gene probes identified as differentially 
expressed in EAMG among DIA, EDL and EOM.  The three independent replicates of 
each group are represented.  Expression ratios are color-coded. The scale at the right 
denotes normalized expression levels (red, high expression; blue, low expression) 
 
Figure 3. The aggregate DLI of the three muscles for EAMG illustrate disease 
progression by summing the absolute values of fold changes of differentially regulated 
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